Alleviating the storm: Ruxolitinib in HLH

Blood

Volumn 127, Issue 13, 2016, Pages 1626-1627

  La Rosée, Paul ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; RUXOLITINIB; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; JANUS KINASE; PYRAZOLE DERIVATIVE;

ARTICLE; GENE EXPRESSION; HEMOPHAGOCYTIC SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE ACTIVATION SYNDROME; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLENOMEGALY; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; INFLAMMATION; LYMPHOCYTE ACTIVATION; PATHOLOGY;

ANIMALS; INFLAMMATION; JANUS KINASES; LYMPHOCYTE ACTIVATION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; PYRAZOLES;

EID: 84963626003     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-02-697151     Document Type: Article

References (10)

1. Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127(13):1666-1675.
2. Allen CE, McClain KL. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program. 2015;2015(1):177-182.
3. La Rosée P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology Am Soc Hematol Educ Program. 2015;2015(1):190-196.
4. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.
5. Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015;26(3):263-280.
6. Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015;126(19):2186-2192.
7. Jordan M, Locatelli F, Allen C, et al. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNg) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH [abstract]. Blood. 2015;126 (23). Abstract LBA-3.
8. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
9. Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832-3842.
10. Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062-2068.